Skip to main content

Table 3 Prevalence of MSP1 antibodies seropositivity in children who never received SMC and children that SMC for 1, 2 and 3 years

From: Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali

 

n

%

95% CI

Unadjusted

Adjusteda

OR

95% CI

p

OR

95% CI

p

No SMC

145

91.7

87.4–96.1

Ref

Ref

SMC 1Y

225

83.0

78.5–87.5

0.43

0.24–0.84

0.013

0.47

0.24–0.92

0.028

SMC 2Y

195

84.1

79.3–88.8

0.47

0.24–0.92

0.028

0.52

0.26–1.03

0.068

SMC 3Y

202

87.4

83.1–91.8

0.62

0.31–1.24

0.18

0.71

0.35–1.43

0.34

SMC 1–3Y

622

84.7

0.82–0.87

0.49

0.27–0.90

0.023

0.55

0.29–1.01

0.05

  1. SMC 1Y received SMC for 1 year, SMC 2Y received SMC for 2 years, SMC 3Y received SMC for 3 years, SMC 1–3Y received SMC for 1, 2, or 3 years
  2. aAdjusted for age, gender and malaria infection